Therapeutic effect of probiotics combined with furazolidone quadruple therapy for eradication of Helicobacter pylori
LIU Jiping1,XIN Ming2,ZHANG Bin2,ZHAO Hongyan3,YANG Guangyu2,SHAN Yuli2,and ZHAO Rui3
1. Second Department of Inner Medicine, 2. First Department of Inner Medicine, Jilin Provincial Corps Hospital of Chinese People’s Armed Police Force, Changchun 130052, China; 3. Department of Gastroenterology, Characteristics Medical Center of Chinese People’s Armed Police Force, Tianjin 300162, China
Abstract：Objective To analyze the effect of probiotics combined with furazolidone quadruple therapy on eradication of Helicobacter pylori (Hp). Methods A total of 403 Hp-positive new recruits were selected from two batches from March to October 2022 and were divided into control group and observation group using a random number table. The control group received rabeprazole enteric-coated capsules at a dose of 20 mg, twice daily before breakfast and dinner, amoxicillin at a dose of 1000 mg, twice daily after breakfast and dinner, furazolidone at a dose of 0.1 g, twice daily after breakfast and dinner, and colloidal bismuth pectin capsules at a dose of 200 mg, twice daily before breakfast and dinner. The treatment duration was 14 days. The observation group received the same quadruple therapy plus probiotics (bifidobacterium quadruple active tablets) at a dose of 3 tablets, three times daily. After a 4-week drug withdrawal, the 13C breath test was conducted to evaluate the Hp eradication rate. Adverse reactions during treatment were monitored and summarized for statistical analysis. Results The Hp eradication rate in the control group was 88.06% (ITT analysis) and 87.13% (ITT analysis) in the observation group, with no statistically significant difference between the two groups (χ2=0.080,P=0.777). The PP analysis showed eradication rates of 88.06% in the control group and 87.56% in the observation group, with no statistically significant difference (χ2=0.023,P=0.879). The incidence of adverse reactions was 15.4% in the control group and 8.9% in the observation group, with a significant difference in the occurrence of adverse reactions (χ2=4.000,P=0.045). Conclusions Probiotics combined with furazolidone quadruple therapy can reduce the incidence of adverse reactions, but do not significantly improve the eradication rate.
Sugano K,Tack J,Kuipers E J,et al.Kyoto global consensus report on Helicobacter pylori gastritis[J].Gut, 2015,64(9):1353-1367.
[4]
Malfertheiner P,Megraud F,O’Morain C A,et al.Management of helicobater pylori infection-the maastricht v/florence consensus report[J].Gut,2017,66(1):6-30.
[5]
Chinese Society of Gastroenterology,Chinese Study Group on Helicobacter Pylori and Peptic Ulcer.Fifth Chinese national consensus report on the management of helicobacter pylori infection[J].Helicobacter,2018,23(2): e12475.
Gao W,Cheng H,Hu F,et al.The evolution of helicobacter antibiotics resistance over 10 years in Beijing,China[J].Helicobacter,2010,15(5):460-466.
[8]
Ermis F,Senocak T E.Current helicobacter pylori treatment in 2014[J].World J Methodol,2015,5(2):101-107.
[9]
Hauser G,Salkic N,Vukelic K,et al.Probiotics for standard triple helicobacter pylori eradication:a randomized,double-blind,placebo-controlled trial[J].Medicine(Baltimore),2015,94(17): e685.
[10]
Zhang Y,Zhou L,Song Z,et al.Primary antibiotic resistance of helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing:a prospective serial study[J].World J Gastroenterol,2015,21(9): 2786-2792.
[11]
Liu D,Wang Y,Zeng Z,et al.Primary antibiotic resistance of Helicobacter pylori in Chinese patients:a multiregion prospective 7-year study[J].Clin Microbiol Infect,2018,(24)7:e5-e8.
[12]
Zhuge L,Wang Y, Wu S,et al.Furazolidone treatment for helicobacter pylori infection:a systematic review and metaanalysis[J].Helicobacter,2018,23(2): e12468.
[13]
Emara M,Elhawari S,Yousef S,et al.Emerging role of probiotics in the management of helicobacter pylori infection:hisopathologic perspectives[J].Helicobacter,2016,21(1):3-10.
[14]
Techo S,Visessanguan W,Vilaichone R K,et al. Characterization and antibacterial activity against helicobacter pylori of lactic acid bacteria isolated from Thai fermented rice noodle[J].Probiotics Antimicro,2019,11(1):92-102.
[15]
Turroni F,Ventura M,Butto’ L,et al.Molecular dialogue between the human gut microbiota and the host:a lactobacillus and Bifidobacterium perspective[J]. Cell Mol Life Sci,2014,71(2):183-203.
Shi X,Zhang J,Mo L,et al.Efficacy and safety of probiotics in eradicating Helicobacter pylori: a network meta- analysis[J]. Medicine(Baltimore),2019,98(15): e15180.
Jakobsson H,Jernberg C,Andersson A,et al.Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome[J].PLoS One,2010,5(3):e9836.
2023, Vol. 34 
